Degirmencioglu Halil, Oncel Mehmet Yekta, Calisici Erhan, Say Birgul, Uras Nurdan, Dilmen Ugur
J Pediatr Ophthalmol Strabismus. 2014 Jul 8;51 Online:e44-7. doi: 10.3928/01913913-20140701-02.
Very low birth weight (VLBW) infants have ophthalmologic examinations for retinopathy of prematurity (ROP) prior to discharge, with appropriate follow-up and intervention where appropriate. Eye drops such as cylopentolate, tropicamide, and phenylephrine are used at different concentrations to provide proper pupil dilation for screening ROP. Topical instillation of eye drops may cause mild or severe ocular or systemic adverse effects. Early recognition of systemic toxicity after eye drop instillation is important. The authors present a case of a VLBW infant who developed significant abdominal symptoms (mimicking ileus) that were significant enough to discontinue oral feeding after ocular instillation of 0.5% tropicamide and 2.5% phenylephrine eye drops for routine examination of ROP. After structural and functional gastrointestinal disorders and sepsis were excluded, symptoms resolved completely after discontinuation of the drug. This report is thought to be the first in the medical literature to address 5% tropicamide and 2.5% phenylephrine eye drops, and the combination that may lead to serious complication after ROP examinations.
极低出生体重(VLBW)婴儿在出院前会接受早产儿视网膜病变(ROP)的眼科检查,并在适当情况下进行相应的随访和干预。诸如环喷托酯、托吡卡胺和去氧肾上腺素等滴眼液会以不同浓度使用,以提供适当的瞳孔散大用于ROP筛查。局部滴注滴眼液可能会引起轻度或严重的眼部或全身不良反应。早期识别滴眼液滴注后的全身毒性很重要。作者报告了一例VLBW婴儿的病例,该婴儿在为进行ROP常规检查而滴注0.5%托吡卡胺和2.5%去氧肾上腺素滴眼液后出现了严重的腹部症状(类似肠梗阻),严重到足以停止口服喂养。在排除了结构性和功能性胃肠道疾病以及败血症后,停药后症状完全缓解。本报告被认为是医学文献中首例涉及5%托吡卡胺和2.5%去氧肾上腺素滴眼液以及ROP检查后可能导致严重并发症的联合用药的报道。